KAZIA THERAPEUTICS-SPON ADR (KZIA)
US48669G1058 - ADR
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Kazia concludes Phase 1 study for paxalisib early due to promising data (NASDAQ:KZIA)
Kazia (KZIA) said it has concluded a Phase 1 trial for its drug paxalisib in the treatment of a certain type of brain metastases early due to encouraging data. Read more here.
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on...
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma...
Kazia Therapeutics files to sell 591,697 ADSs for holders (NASDAQ:KZIA)
Learn about Kazia Therapeutics (KZIA) prospectus filing for resale of American Depositary Shares (ADSs) by a selling shareholder.
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced the closing...
Kazia Therapeutics falls after announcing $2M direct offering (NASDAQ:KZIA)
Kazia Therapeutics enters a deal to purchase and sell 4.44M American Depositary Shares at $0.45 per ADS, with additional warrants at $0.583 per ADS.
Kazia Therapeutics Announces $2 Million Registered Direct Offering
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
Kazia stock jumps after proposed license deal for paxalisib outside oncology (NASDAQ:KZIA)
Kazia Therapeutics signs non-binding letter of intent for worldwide rights to develop and commercialize paxalisib, a potential brain cancer treatment,...
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has signed a...
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical...
Kazia Therapeutics gets deficiency notice from Nasdaq (NASDAQ:KZIA)
Kazia Therapeutics receives deficiency notification from Nasdaq due to non-compliance with minimum bid price requirement.
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a deficiency notification from the Listing Qualifications Staff of...
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that the Society of...
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the trading week right with a breakdown of the biggest pre-market stock movers worth noting on Monday morning!
Kazia issues update on paxalisib study in CNS lymphoma patients (NASDAQ:KZIA)
Kazia Therapeutics provides preliminary update on its ongoing phase 2 study of paxalisib, a brain cancer treatment, leading to a premarket stock gain of...
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide a preliminary update...
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that selected clinical data from...